http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 23 Jun 2026 14:09:02 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Coherus+and+Zumutor+to+run+Phase+1+trial+combining+ZM008+and+Loqtorzi/26678826.html <p>Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. announced a clinical collaboration and supply agreement to conduct a Phase 1 trial evaluating ZM008, an anti-LLT1 monoclonal antibody, in combination with Coherus' PD-1 inhibitor LOQTORZI (toripalimab-tpzi), according to a press release.</p><p>The trial (NCT06451497) will enroll up to 45 patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma, urothelial cancers, and other solid tumors across dose-escalation and expansion cohorts in the United States. The study will assess safety, tolerability, and the recommended dose of ZM008.</p><p>Under the agreement, Coherus Oncology will supply LOQTORZI to Zumutor, which http://www.streetinsider.com/Corporate+News/Coherus+and+Zumutor+to+run+Phase+1+trial+combining+ZM008+and+Loqtorzi/26678826.html Tue, 23 Jun 2026 14:09:02 -0400 CHRS http://www.streetinsider.com/FDA/Coherus+and+Zumutor+to+run+Phase+1+trial+combining+ZM008+and+Loqtorzi/26678826.html <p>Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. announced a clinical collaboration and supply agreement to conduct a Phase 1 trial evaluating ZM008, an anti-LLT1 monoclonal antibody, in combination with Coherus' PD-1 inhibitor LOQTORZI (toripalimab-tpzi), according to a press release.</p><p>The trial (NCT06451497) will enroll up to 45 patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma, urothelial cancers, and other solid tumors across dose-escalation and expansion cohorts in the United States. The study will assess safety, tolerability, and the recommended dose of ZM008.</p><p>Under the agreement, Coherus Oncology will supply LOQTORZI to Zumutor, which http://www.streetinsider.com/FDA/Coherus+and+Zumutor+to+run+Phase+1+trial+combining+ZM008+and+Loqtorzi/26678826.html Tue, 23 Jun 2026 14:09:02 -0400 CHRS http://www.streetinsider.com/Press+Releases/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html <p align="justify">REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc.</strong> (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor (Trial ID: NCT06451497). The study will enroll patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers, among other solid tumors.</p> <p align="justify">“We are excited to partner with Zumutor Biologics on the development http://www.streetinsider.com/Press+Releases/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html Tue, 23 Jun 2026 14:00:00 -0400 A.50216997 CHRS O.13850153 O.57148086 http://www.streetinsider.com/Press+Releases/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html <p align="justify">REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc.</strong> (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor (Trial ID: NCT06451497). The study will enroll patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers, among other solid tumors.</p> <p align="justify">“We are excited to partner with Zumutor Biologics on the development http://www.streetinsider.com/Press+Releases/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html Tue, 23 Jun 2026 14:00:00 -0400 A.50216997 CHRS O.13850153 O.57148086 http://www.streetinsider.com/Press+Releases/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html <p align="justify">REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc.</strong> (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor (Trial ID: NCT06451497). The study will enroll patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers, among other solid tumors.</p> <p align="justify">“We are excited to partner with Zumutor Biologics on the development http://www.streetinsider.com/Press+Releases/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html Tue, 23 Jun 2026 14:00:00 -0400 A.50216997 CHRS O.13850153 O.57148086 http://www.streetinsider.com/Press+Releases/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html <p align="justify">REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc.</strong> (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor (Trial ID: NCT06451497). The study will enroll patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers, among other solid tumors.</p> <p align="justify">“We are excited to partner with Zumutor Biologics on the development http://www.streetinsider.com/Press+Releases/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html Tue, 23 Jun 2026 14:00:00 -0400 A.50216997 CHRS O.13850153 O.57148086 http://www.streetinsider.com/Globe+Newswire/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html <p align="justify">REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc.</strong> (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor (Trial ID: NCT06451497). The study will enroll patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers, among other solid tumors.</p> <p align="justify">“We are excited to partner with Zumutor Biologics on the development http://www.streetinsider.com/Globe+Newswire/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html Tue, 23 Jun 2026 14:00:00 -0400 A.50216997 CHRS O.13850153 O.57148086 http://www.streetinsider.com/Globe+Newswire/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html <p align="justify">REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc.</strong> (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor (Trial ID: NCT06451497). The study will enroll patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers, among other solid tumors.</p> <p align="justify">“We are excited to partner with Zumutor Biologics on the development http://www.streetinsider.com/Globe+Newswire/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html Tue, 23 Jun 2026 14:00:00 -0400 A.50216997 CHRS O.13850153 O.57148086 http://www.streetinsider.com/Globe+Newswire/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html <p align="justify">REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc.</strong> (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor (Trial ID: NCT06451497). The study will enroll patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers, among other solid tumors.</p> <p align="justify">“We are excited to partner with Zumutor Biologics on the development http://www.streetinsider.com/Globe+Newswire/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html Tue, 23 Jun 2026 14:00:00 -0400 A.50216997 CHRS O.13850153 O.57148086 http://www.streetinsider.com/Globe+Newswire/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html <p align="justify">REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc.</strong> (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor (Trial ID: NCT06451497). The study will enroll patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers, among other solid tumors.</p> <p align="justify">“We are excited to partner with Zumutor Biologics on the development http://www.streetinsider.com/Globe+Newswire/Coherus+and+Zumutor+Biologics+Announce+Clinical+Collaboration+to+Evaluate+ZM008+in+Combination+with+LOQTORZI%C2%AE+%28toripalimab-tpzi%29/26678794.html Tue, 23 Jun 2026 14:00:00 -0400 A.50216997 CHRS O.13850153 O.57148086 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+12/26648041.html si-local-file:///var/storage/secattach/20260615/26648041.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+12/26648041.html Mon, 15 Jun 2026 16:41:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+12/26648041.html si-local-file:///var/storage/secattach/20260615/26648041.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+12/26648041.html Mon, 15 Jun 2026 16:41:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Satvat+Ali+J./26625402.html si-local-file:///var/storage/secattach/20260609/26625402.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Satvat+Ali+J./26625402.html Tue, 09 Jun 2026 21:58:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Satvat+Ali+J./26625402.html si-local-file:///var/storage/secattach/20260609/26625402.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Satvat+Ali+J./26625402.html Tue, 09 Jun 2026 21:58:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Newcomer+Lee+Nisley/26625114.html si-local-file:///var/storage/secattach/20260609/26625114.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Newcomer+Lee+Nisley/26625114.html Tue, 09 Jun 2026 18:43:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Newcomer+Lee+Nisley/26625114.html si-local-file:///var/storage/secattach/20260609/26625114.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Newcomer+Lee+Nisley/26625114.html Tue, 09 Jun 2026 18:43:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Karachun+Rita+A/26625115.html si-local-file:///var/storage/secattach/20260609/26625115.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Karachun+Rita+A/26625115.html Tue, 09 Jun 2026 18:43:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Karachun+Rita+A/26625115.html si-local-file:///var/storage/secattach/20260609/26625115.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Karachun+Rita+A/26625115.html Tue, 09 Jun 2026 18:43:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+O%26apos%3BDonnell-Tormey+Jill/26625106.html si-local-file:///var/storage/secattach/20260609/26625106.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+O%26apos%3BDonnell-Tormey+Jill/26625106.html Tue, 09 Jun 2026 18:41:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+O%26apos%3BDonnell-Tormey+Jill/26625106.html si-local-file:///var/storage/secattach/20260609/26625106.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+O%26apos%3BDonnell-Tormey+Jill/26625106.html Tue, 09 Jun 2026 18:41:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Ryan+Michael+Lee/26625109.html si-local-file:///var/storage/secattach/20260609/26625109.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Ryan+Michael+Lee/26625109.html Tue, 09 Jun 2026 18:41:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Ryan+Michael+Lee/26625109.html si-local-file:///var/storage/secattach/20260609/26625109.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Ryan+Michael+Lee/26625109.html Tue, 09 Jun 2026 18:41:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Newton+Charles+W./26625100.html si-local-file:///var/storage/secattach/20260609/26625100.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Newton+Charles+W./26625100.html Tue, 09 Jun 2026 18:40:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Newton+Charles+W./26625100.html si-local-file:///var/storage/secattach/20260609/26625100.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Newton+Charles+W./26625100.html Tue, 09 Jun 2026 18:40:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Wahlstrom+Mats/26625103.html si-local-file:///var/storage/secattach/20260609/26625103.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+05++Filed+by%3A+Wahlstrom+Mats/26625103.html Tue, 09 Jun 2026 18:40:00 -0400 CHRS O.13850153